Misonix to Participate in Three Upcoming Investor Conferences

FARMINGDALE, N.Y., Nov. 08, 2018 (GLOBE NEWSWIRE) — Misonix, Inc. (NASDAQ: MSON) (“Misonix” or the “Company”), a provider of minimally invasive therapeutic ultrasonic medical devices that enhance clinical outcomes, today announced that management will be participating in three upcoming investor conferences:

• Craig-Hallum Alpha Select Conference
  • Date: Thursday, November 15, 2018
  • Location: Sheraton New York Times Square Hotel, New York, N.Y.
     
• Canaccord Genuity Medical Technologies & Diagnostics Forum
  • Date: Thursday, November 15, 2018
  • Location: Westin Grand Central Hotel, New York, N.Y.
     
• Piper Jaffray 30^th Annual Healthcare Conference
  • Date: Wednesday, November 28, 2018
  • Location: Lotte New York Palace Hotel, New York, N.Y.

Misonix President and Chief Executive Officer, Stavros Vizirgianakis, along with Joe Dwyer, Misonix Chief Financial Officer, will be available to meet with institutional investors in one-on-one meetings throughout the day.

The Misonix investor presentation is available in the “Investor Relations” section of the Company’s website at www.misonix.com. If you have questions about Misonix or are interested in conducting a conference call or meeting with management, please contact the Company’s investor relations firm, JCIR, at (212) 835-8500 or via email at mson@jcir.com.

About Misonix, Inc.
Misonix, Inc. (NASDAQ: MSON) designs, manufactures and markets ultrasonic medical devices for the precise removal of hard and soft tissue, including bone removal, wound debridement and ultrasonic aspiration. Misonix is focused on leveraging its proprietary ultrasonic technology to become the standard of care in operating rooms and clinics around the world. Misonix’s proprietary ultrasonic medical devices are used in a growing number of medical procedures, including spine surgery, neurosurgery, orthopedic surgery, cosmetic surgery, laparoscopic surgery, and other surgical and medical applications. At Misonix, Better Matters to us. That is why throughout the Company’s history, Misonix has maintained its commitment to medical technology innovation and the development of ultrasonic surgical products that radically improve patient outcomes. Additional information is available on the Company’s web site at www.misonix.com.